CytomX Therapeutics (NASDAQ:CTMX) Rating Reiterated by HC Wainwright

CytomX Therapeutics (NASDAQ:CTMX)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a report released on Thursday, Benzinga reports.

Several other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. raised CytomX Therapeutics from an “underweight” rating to a “neutral” rating in a research note on Monday, April 22nd. StockNews.com cut CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Wedbush raised CytomX Therapeutics from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $3.00 to $8.00 in a research note on Thursday. BMO Capital Markets reissued a “market perform” rating and set a $3.25 target price on shares of CytomX Therapeutics in a research note on Wednesday, May 1st. Finally, Jefferies Financial Group upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the stock from $2.50 to $8.00 in a research report on Monday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $6.42.

CytomX Therapeutics Price Performance

Shares of NASDAQ:CTMX traded down $1.75 during midday trading on Thursday, hitting $2.44. The company had a trading volume of 13,075,612 shares, compared to its average volume of 4,026,503. CytomX Therapeutics has a twelve month low of $1.04 and a twelve month high of $5.85. The stock has a market cap of $166.26 million, a price-to-earnings ratio of -124.00 and a beta of 1.09. The business’s 50-day simple moving average is $2.38 and its 200-day simple moving average is $1.78.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, March 11th. The biotechnology company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.02 by ($0.01). The company had revenue of $26.61 million during the quarter, compared to analysts’ expectations of $23.36 million. As a group, sell-side analysts forecast that CytomX Therapeutics will post -0.25 EPS for the current year.

Insider Transactions at CytomX Therapeutics

In other news, CEO Sean A. Mccarthy sold 20,223 shares of CytomX Therapeutics stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total transaction of $42,266.07. Following the sale, the chief executive officer now owns 524,481 shares in the company, valued at $1,096,165.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 35,024 shares of company stock valued at $73,200. 7.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Susquehanna Fundamental Investments LLC acquired a new stake in shares of CytomX Therapeutics during the 1st quarter valued at approximately $124,000. SG Americas Securities LLC acquired a new position in CytomX Therapeutics during the first quarter worth about $57,000. Congress Park Capital LLC lifted its holdings in shares of CytomX Therapeutics by 112.8% in the fourth quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company’s stock valued at $371,000 after purchasing an additional 126,850 shares in the last quarter. AlphaMark Advisors LLC lifted its stake in CytomX Therapeutics by 119.8% in the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 12,635 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in CytomX Therapeutics by 737.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 234,970 shares during the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.